Table 1.
Clinical characteristics of the study subjects
| Variables | Normal (n = 692) |
NTIS (n = 139) |
Renal dysfunction (n = 304) | Combined (n = 160) | P value | P value* |
|---|---|---|---|---|---|---|
| Age (years) | 65 ± 13 | 70 ± 12 | 75 ± 9 | 77 ± 10 | < 0.001 | < 0.001 |
| Male(n,%) | 536 (77.5%) | 78 (56.1%) | 147 (48.4%) | 97 (60.6%) | < 0.001 | 0.001 |
| Hypertension(n,%) | 403 (58.2%) | 83 (59.7%) | 227 (74.7%) | 107 (66.9%) | < 0.001 | 0.112 |
| Diabetes mellitus (n,%) | 181 (26.2%) | 46 (33.1%) | 111 (36.5%) | 61 (38.1%) | 0.001 | 0.001 |
| Smoking(n,%) | 452 (65.5%) | 82 (59.0%) | 150 (49.3%) | 81 (50.6%) | < 0.001 | 0.083 |
| Alcohol(n,%) | 50 (7.3%) | 5 (3.6%) | 7 (2.3%) | 6 (3.8%) | 0.006 | 0.597 |
| SBP (mmHg) | 128 ± 22 | 123 ± 23 | 132 ± 24 | 127 ± 26 | 0.003 | < 0.001 |
| DBP (mmHg) | 75 ± 13 | 70 ± 13 | 73 ± 13 | 72 ± 14 | 0.001 | < 0.001 |
| BMI (kg/m2) | 24.24 ± 2.04 | 23.36 ± 2.53 | 23.55 ± 2.53 | 23.46 ± 2.66 | < 0.001 | 0.03 |
| WBC (×109/l) | 8.64 ± 3.69 | 9.71 ± 4.90 | 8.30 ± 3.98 | 9.98 ± 4.91 | < 0.001 | < 0.001 |
| Hb (g/l) | 139 ± 15 | 129 ± 16 | 124 ± 17 | 116 ± 20 | < 0.001 | < 0.001 |
| Alb (g/l) | 41 ± 6 | 38 ± 6 | 40 ± 5 | 37 ± 6 | < 0.001 | 0.001 |
| CRP (mg/l) | 3.4 (1.6–6.5) | 10.0 (4.8–21.3) | 5.1 (3.5–8.0) | 18.2 (8.8–33.0) | < 0.001 | < 0.001 |
| TG (mmol/l) | 1.54 ± 0.91 | 1.37 ± 1.07 | 1.40 ± 0.80 | 1.30 ± 0.91 | < 0.001 | 0.005 |
| TC (mmol/l) | 4.60 ± 1.15 | 4.64 ± 1.15 | 4.34 ± 1.14 | 4.24 ± 1.17 | 0.007 | < 0.001 |
| HDL-C(mmol/l) | 1.05 (0.90–1.22) | 1.05 (0.93–1.21) | 1.06 (0.85–1.23) | 1.03 (0.87–1.20) | 0.361 | 0.245 |
| LDL-C(mmol/l) | 2.92 (2.34–3.55) | 2.80 (2.23–3.55) | 2.67 (2.09–3.44) | 2.56 (2.02–3.25) | < 0.001 | 0.547 |
| FPG (mmol/l) | 6.98 ± 3.30 | 7.95 ± 3.65 | 7.10 ± 3.31 | 7.60 ± 3.07 | 0.003 | 0.007 |
| FT3(pmol/l) | 4.05 ± 0.55 | 2.60 ± 0.47 | 3.88 ± 0.53 | 2.52 ± 0.46 | < 0.001 | < 0.001 |
| FT4(pmol/l) | 16.15 ± 2.23 | 15.26 ± 2.06 | 16.52 ± 2.30 | 15.17 ± 2.53 | < 0.001 | < 0.001 |
| TSH(mU/l) | 1.30 (0.75–2.12) | 1.26 (0.57–1.94) | 1.47 (0.98–2.29) | 1.25 (0.59–1.84) | < 0.001 | 0.004 |
| sCr (μmol/l) | 76 (65–88) | 74 (60–89) | 118 (102–142) | 135 (109–178) | < 0.001 | < 0.001 |
| eGFR(ml/min/1.73m2) | 89.69 ± 29.58 | 86.77 ± 28.15 | 44.03 ± 12.90 | 39.84 ± 14.50 | < 0.001 | < 0.001 |
| Antiplatelet agents(n,%) | 446 (64.6%) | 93 (66.9%) | 180 (59.2%) | 96 (60.0%) | 0.241 | 0.491 |
| β-blockers(n,%) | 379 (55.0%) | 77 (55.4%) | 217 (71.4%) | 110 (68.8%) | < 0.001 | 0.005 |
| LLDs (n,%) | 462 (67.0%) | 95 (68.3%) | 158 (52.1%) | 92 (57.5%) | < 0.001 | 0.040 |
| ACEIs/ARBs(n,%) | 363 (52.6%) | 89 (64.0%) | 140 (46.2%) | 70 (43.8%) | 0.001 | 0.133 |
| CCBs (n,%) | 81 (11.7%) | 12 (8.6%) | 39 (12.8%) | 19 (11.9%) | 0.649 | 0.922 |
| Diuretics(n,%) | 492 (71.2%) | 116 (83.5%) | 210 (69.1%) | 114 (71.3%) | 0.014 | 0.873 |
| Revascularization during the present hospitalization(n,%) | 539 (77.9%) | 98 (70.5%) | 163 (53.6%) | 68 (42.5%) | < 0.001 | < 0.001 |
| Prior PCI or CABG (n,%) | 24 (3.5%) | 4 (2.9%) | 6 (2.0%) | 6 (3.8%) | 0.604 | 0.622 |
| Infarct type (NSTEMI n,%) | 42 (6.1%) | 11 (7.9%) | 17 (5.6%) | 12 (7.5%) | 0.725 | 0.627 |
Values are expressed as mean ± SD,median with interquartile range or percentages
The p values were not adjusted for age and sex for the trend
The p values* were adjusted for age and sex for the trend
Revascularization included percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG)